Aldeyra Therapeutics Inc
ALDX4.935USD
+0.125+2.60%
Market hours （ET）Quotes delayed by 15 min
296.32MMarket Cap
LossP/E TTM
More Details of Aldeyra Therapeutics Inc Company
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Company Info
Ticker SymbolALDX
Company nameAldeyra Therapeutics Inc
IPO dateMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Number of employees9
Security typeOrdinary Share
Fiscal year-endMay 02
Address131 Hartwell Avenue
CityLEXINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02421
Phone17817614904
Websitehttps://www.aldeyra.com/
Ticker SymbolALDX
IPO dateMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Ben R. Bronstein, M.D.
Dr. Ben R. Bronstein, M.D.
Independent Director
Independent Director
--
--
Ms. Nancy B. Miller-Rich
Ms. Nancy B. Miller-Rich
Independent Director
Independent Director
--
--
Mr. William (Chip) Clark
Mr. William (Chip) Clark
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Alfieri
Mr. Michael (Mike) Alfieri
Principal Financial Officer and Principal Accounting Officer
Principal Financial Officer and Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
9.14%
Perceptive Advisors LLC
8.14%
The Vanguard Group, Inc.
6.21%
BlackRock Institutional Trust Company, N.A.
5.70%
Ardsley Advisory Partners LP
2.92%
Other
67.89%
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
9.14%
Perceptive Advisors LLC
8.14%
The Vanguard Group, Inc.
6.21%
BlackRock Institutional Trust Company, N.A.
5.70%
Ardsley Advisory Partners LP
2.92%
Other
67.89%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.59%
Hedge Fund
16.52%
Investment Advisor/Hedge Fund
9.81%
Private Equity
8.14%
Individual Investor
3.13%
Research Firm
2.42%
Pension Fund
0.17%
Bank and Trust
0.10%
Family Office
0.08%
Other
40.04%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
293
35.88M
59.90%
-7.96M
2025Q1
315
40.31M
67.37%
-4.94M
2024Q4
306
39.84M
66.72%
-5.42M
2024Q3
295
38.52M
64.82%
-5.60M
2024Q2
290
37.23M
62.65%
-8.21M
2024Q1
294
37.04M
62.88%
-7.70M
2023Q4
296
36.84M
62.63%
-6.52M
2023Q3
298
39.89M
68.07%
-12.41M
2023Q2
305
41.03M
70.05%
-8.66M
2023Q1
311
38.11M
64.83%
-12.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knoll Capital Management, LLC
5.48M
9.14%
--
--
Mar 31, 2025
Perceptive Advisors LLC
4.88M
8.14%
-4.40M
-47.44%
Apr 03, 2025
The Vanguard Group, Inc.
3.72M
6.21%
-38.77K
-1.03%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.41M
5.7%
-50.91K
-1.47%
Mar 31, 2025
Ardsley Advisory Partners LP
1.75M
2.92%
+600.00K
+52.17%
Mar 31, 2025
Brady (Todd C)
1.42M
2.38%
+267.69K
+23.16%
Apr 14, 2025
Kennedy Capital Management LLC
1.23M
2.06%
-235.10K
-16.01%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.14M
1.9%
+18.27K
+1.63%
Mar 31, 2025
State Street Global Advisors (US)
1.02M
1.71%
-11.99K
-1.16%
Mar 31, 2025
Kingdon Capital Management, L.L.C.
779.00K
1.3%
+779.00K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.8%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Vanguard US Momentum Factor ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.8%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
Vanguard US Momentum Factor ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
